💨 Abstract

Indian generic drugmaker Lupin reported a 74% increase in Q2 profit, driven by strong demand for respiratory and diabetes drugs. Net profit rose to 8.53 billion rupees, exceeding analyst estimates, with revenue growing 11.3% to 54.97 billion rupees. The company's revenue largely comes from the US, the world's largest pharmaceutical market.

Courtesy: theprint.in